Temporal trends and hospital variation in the use of P2Y12 inhibitors among patients undergoing percutaneous coronary intervention: Insights from the VA CART program.

Catheterization and Cardiovascular InterventionsEarly View LETTER TO THE EDITOR Temporal trends and hospital variation in the use of P2Y12 inhibitors among patients undergoing percutaneous coronary intervention: Insights from the VA CART program Bilal Aijaz MD, Bilal Aijaz MD Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USASearch for more papers by this authorThomas J. Glorioso MS, Thomas J. Glorioso MS CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, District of Columbia, USASearch for more papers by this authorNeel Butala MD, Neel Butala MD Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USASearch for more papers by this authorStephen W. Waldo MD, Corresponding Author Stephen W. Waldo MD [email protected] Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USA CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, District of Columbia, USA Correspondence Stephen W. Waldo, MD, Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Suite F2-166, Aurora, CO 80045, USA. Email: [email protected]Search for more papers by this author Bilal Aijaz MD, Bilal Aijaz MD Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USASearch for more papers by this authorThomas J. Glorioso MS, Thomas J. Glorioso MS CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, District of Columbia, USASearch for more papers by this authorNeel Butala MD, Neel Butala MD Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USASearch for more papers by this authorStephen W. Waldo MD, Corresponding Author Stephen W. Waldo MD [email protected] Division of Cardiology, Department of Medicine, University of Colorado, Aurora, Colorado, USA Department of Medicine, VA Eastern Colorado Health Care System, Aurora, Colorado, USA CART Program, Office of Quality and Patient Safety, Veterans Health Administration, Washington, District of Columbia, USA Correspondence Stephen W. Waldo, MD, Rocky Mountain Regional VA Medical Center, 1700 N Wheeling St, Suite F2-166, Aurora, CO 80045, USA. Email: [email protected]Search for more papers by this author First published: 20 July 2023 https://doi.org/10.1002/ccd.30782Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014; 35: 2541-2619. 2Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention, 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016; 134: 123-155. 3Karve AM, Seth M, Sharma M, et al. Contemporary use of ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol. 2015; 115: 1502-1506. 4Schüpke S, Neumann F-J, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019; 381: 1524-1534. 5Faridi KF, Garratt KN, Kennedy KF, et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment-elevation myocardial infarction in the United States: a study from The National Cardiovascular Data Registry's Research to Practice Initiative. Circ Cardiovasc Qual Outcomes. 2020; 13:e006275. Early ViewOnline Version of Record before inclusion in an issue SCAI Member Sign in ReferencesRelatedInformation